Retreatment with immunotherapy plus chemo and bevacizumab for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (QL1706, which is an immunotherapy, and paclitaxel, a chemotherapy drug) plus a targeted drug called bevacizumab, for people with advanced stomach cancer that has grown despite a first treatment that included immunotherapy. It aims to see if 'rechallenging' with immunotherapy in a different combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- This trial is for people with advanced stomach cancer or cancer where the stomach meets the esophagus, and it cannot be removed by surgery.
- You must have already received at least three cycles of a first-line treatment that included both a type of immunotherapy (called a PD-1 inhibitor) and chemotherapy.
- Your cancer must have grown or returned within 6 months of finishing that first treatment, or you failed that treatment.
- You need to have a HER2-negative cancer type (this is a specific protein test that your doctor can check).
- You must not have had prior treatment with paclitaxel (a chemotherapy drug) or with drugs that target the VEGF pathway (like bevacizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
This trial tests a new combination of medications (IBI363 plus bevacizumab, with or without nab-paclitaxel) for people with advanced stomach cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth better than existing options.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Hear when a new Gastric Cancer (GC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.